SIBN SI-BONE

SI-BONE To Present at The Morgan Stanley 20th Annual Global Healthcare Conference

SI-BONE To Present at The Morgan Stanley 20th Annual Global Healthcare Conference

SANTA CLARA, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference. Management will be hosting a fireside chat presentation on Wednesday, September 14th, 2022, at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time.

A live webcast of each event, as well as an archived recording will be available on the “Investors” section of the company’s website at: . The webcasts will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since 2009, when SI-BONE introduced the iFuse Implant System for minimally invasive surgery of the SI joint, more than 2,800 surgeons have performed a combined total of more than 70,000 SI joint fusion procedures. A unique body of evidence, supporting the iFuse Implant System, including two randomized controlled trials and over 100 peer reviewed publications, has enabled multiple government and private insurance payors to establish near universal coverage of the SI joint fusion procedure. Supported by this proprietary reimbursement advantage, SI-BONE has actively leveraged its market leadership position in recent years to further clinical research, and evolve and commercialize novel surgical treatment solutions for SI-Joint pain, sacropelvic and pelvic fixation, and pelvic trauma. For more information or to join our team, please visit us at -bone.com.

For additional information on the company or the products including risks and benefits, please visit -bone.com.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2022 SI-BONE, Inc. All Rights Reserved.

Investor Contact:

Matt Bacso, CFA

Media Contact:

Joe Powers



EN
23/08/2022

Underlying

SIBNSI-BONE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SI-BONE

 PRESS RELEASE
Free
SIBN SI-BONE

SI-BONE To Present at BofA Securities 2025 Healthcare Conference on Ma...

SI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025 SANTA CLARA, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 BofA Securities Healthcare Conference in Las Vegas. Management will be hosting a fireside chat on Tuesday, May 13, 2025, at 8:40 a.m. Pacific Time/11:40 a.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: . Live audio of ...

May 6, 2025 1 EN
 PRESS RELEASE
Free
SIBN SI-BONE

SI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and...

SI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 Guidance Achieved ~25% worldwide revenue growth and positive adjusted EBITDA First Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $47.3 million, representing growth of 24.9%U.S. revenue of $44.8 million, representing growth of 26.6%Gross margin of 79.7%, representing an improvement of 80 basis pointsNet loss of $6.5 million, representing an improvement of 40.0%Positive adjusted EBITDA of $0.5 million$144.4 million in cash and...

May 5, 2025 1 EN
 PRESS RELEASE
Free
SIBN SI-BONE

SI-BONE To Report First Quarter 2025 Financial Results on May 5, 2025

SI-BONE To Report First Quarter 2025 Financial Results on May 5, 2025 SANTA CLARA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the first quarter of 2025 after market close on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: . Live audio of the webcast will be available on...

April 14, 2025 1 EN
 PRESS RELEASE
Free
SIBN SI-BONE

SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter ...

SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance Achieves 26% worldwide revenue growth and positive adjusted EBITDA in Fourth Quarter 2024 SANTA CLARA, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $49.0 million, representing growth of ~26%  ...

February 24, 2025 1 EN
 PRESS RELEASE
Free
SIBN SI-BONE

SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results ...

SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025 SANTA CLARA, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, February 24, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this...

February 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch